Physician profile
Karyn Haitz
NPI 1962932384
$10,228.91
in general payments reported to CMS, 2019-2025
34 companies · $2,965 in 2025
The $2,965 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,742 · 2020: $354 · 2021: $145 · 2022: $981 · 2023: $1,313 · 2024: $2,728 · 2025: $2,965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,890 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,890.35 |
| Education | $115.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,126.99 | 2019-2025 | |
| Janssen Biotech, INC. | $1,043.77 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Amgen INC. | $937.15 | 2022-2025 | Otezla, Otezla |
| Genzyme Corporation | $675.49 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $580.43 | 2019-2025 | |
| Allergan, INC. | $478.51 | 2019-2022 | |
| Lilly USA, LLC | $456.05 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $397.93 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $389.24 | 2023-2025 | Adbry, Anzupgo, Spevigo |
| Incyte Corporation | $380.42 | 2023-2025 | Opzelura |
| Galderma Laboratories, L.P. | $370.31 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Sun Pharmaceutical Industries INC. | $349.63 | 2023-2025 | Ilumya |
| Mimedx Group, INC. | $340.62 | 2025 | |
| Pfizer INC. | $301.74 | 2022-2025 | |
| Genentech USA, INC. | $226.78 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $218.18 | 2024-2025 | Bimzelx |
| Dermavant Sciences, INC. | $146.79 | 2022-2024 | Vtama |
| Almirall LLC | $138.65 | 2024 | Klisyri |
| E.R. Squibb & Sons, L.L.C. | $117.35 | 2022-2025 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.94 | 2022-2024 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $90.87 | 2019-2025 | Cabtreo, Jublia, Siliq |
| Epi Health, LLC | $45.07 | 2022 | |
| Biofrontera INC. | $41.74 | 2020-2022 | |
| Boston Scientific Corporation | $41.73 | 2023 | Wavewriter Alpha Prime 16 |
| Arcutis Biotherapeutics, INC. | $39.83 | 2024-2025 | Zoryve |
| Kyowa Kirin, INC. | $38.61 | 2019-2025 | |
| Botanix Sb INC | $33.36 | 2025 | Sofdra |
| Solta Medical, A Division of Bausch Health US, LLC | $25.79 | 2025 | |
| Revance Therapeutics, INC. | $20.37 | 2024 | Daxxify |
| Journey Medical Corporation | $20.07 | 2023 | |
| Cipher Pharmaceuticals US LLC | $19.68 | 2025 | Natroba, Spinosad |
| Strata Skin Sciences, INC. | $18.25 | 2025 | Xtrac |
| Sensus Healthcare, INC. | $9.23 | 2019 | |
| Mayne Pharma Commercial LLC | $5.34 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karyn Haitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.